Compare WMK & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WMK | GLTO |
|---|---|---|
| Founded | 1912 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 1994 | 2020 |
| Metric | WMK | GLTO |
|---|---|---|
| Price | $62.25 | $28.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $43.67 |
| AVG Volume (30 Days) | 127.7K | ★ 362.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.21% | N/A |
| EPS Growth | ★ 5.96 | N/A |
| EPS | ★ 2.51 | N/A |
| Revenue | ★ $4,714,573,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.70 | ★ N/A |
| Revenue Growth | ★ 0.01 | N/A |
| 52 Week Low | $61.27 | $2.01 |
| 52 Week High | $90.23 | $38.33 |
| Indicator | WMK | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 51.77 |
| Support Level | N/A | $24.53 |
| Resistance Level | $68.14 | $32.86 |
| Average True Range (ATR) | 2.29 | 2.50 |
| MACD | -1.04 | -0.30 |
| Stochastic Oscillator | 6.14 | 29.94 |
Weis Markets Inc is a U.S.-based company that is principally engaged in retailing food products in Pennsylvania and surrounding states. The company's products mainly belong to the following categories: center-store goods, fresh goods, pharmacy services, fuel, and others. The center-store goods include groceries, dairy products, frozen foods, alcoholic beverages, and general merchandise items. The fresh goods include meats, seafood, floral, prepared foods, and bakery products. The center-store goods and fresh goods jointly account for the majority of the company's total revenue.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.